Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes

Sharif, Najam A.; McLaughlin, Marsha A.; Kelly, Curtis R.; Katoli, Parvaneh; Drace, Colene; Husain, Shahid; Crosson, Craig E.; Toris, Carol B.; Zhan, G.; Camras, Carl B.

doi:10.1016/j.exer.2008.10.003

Cited by 39 publications

(50 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is a high affinity for the D2 receptor which makes it better tolerated than bromocriptine. Available data in humans confirm the experimental observations in animals indicating that the test compound has a highly selective activity without effect on basal secretion of other pituitary hormones [1,2]. Obsessive compulsive disorder (OCD) is a rare but serious side effects that can result from cabergoline.…”

Section: Discussionsupporting

confidence: 70%

Dostinex® and Obsessive Compulsive Disorder

Aziouaz¹

2017

EMIJ

View full text Add to dashboard Cite

Obsessive Compulsive Disorder (OCD) related to cabergoline Dostinex® gold is one of the uncommon side effects of this product often passing unnoticed Because it is quite unknown. It usually regressed completely Call after-stopping or decreasing Dostinex® and the establishment of a symptomatic treatment. The pathophysiology remains unknown but it Appears That this requirement May be due to dysregulation of neurotransmitters serotonin and dopamine Primarily in the central nervous system. We report the case of an 18 year old patientwho presented a secondary TOC in decision Dostinex® for Treatment of a prolactinoma. This side effect Was Retained accountability Following The study by the department of Pharmacology and Pharmacovigilance. The patient received a dose Then reduction of cabergoline, a psychiatric consultation with initiation of antidepressant therapy: sertraline (of the family of selective serotonin reuptake inhibitors of ). The evolution Was marked by the remission of symptoms.

show abstract

Section: Discussionsupporting

confidence: 70%

Dostinex® and Obsessive Compulsive Disorder

Aziouaz¹

2017

EMIJ

View full text Add to dashboard Cite

show abstract

“…Inc., Ft. Worth, TX] diluted with 0.9% saline) as previously reported (May et al, 2003;Sharif et al, 2009). The right eyes of these monkeys had been rendered ocular hypertensive using a laser trabeculoplasty procedure performed many years ago.…”

Section: Measurement Of Iopmentioning

confidence: 99%

Preclinical pharmacology, ocular tolerability and ocular hypotensive efficacy of a novel non-peptide bradykinin mimetic small molecule

Sharif¹,

Li²,

Katoli³

et al. 2014

Experimental Eye Research

Self Cite

View full text Add to dashboard Cite

“…In vitro studies show that cabergoline binds to rat striatal D 2 receptors more strongly than D 1 receptors (3 versus 11 nmol/L, IC 50 ) and has almost no affinity for rodent serotonin -1 and -2 receptors (170 and 1000 nmol/L, IC 50 ) (205). Although Sharif et al demonstrated that cabergoline is a potent D 2 agonist [0.4n (196)], we cannot entirely discount the possibility that its moderate α 2A [132nM, (196)] binding might be contributing to our SST results via noradrenergic mechanisms.…”

Section: Action Cancellationmentioning

confidence: 70%

“…Cabergoline is a potent D 2 receptor agonist (0.4nM) that has almost no affinity for D 1 (32 000nM) and moderate affinity for α 2A (132nM) (196). Hence the finding that cabergoline was able to improve error awareness behaviour had to be contrasted against potential dopaminergic and noradrenergic mechanisms.…”

Section: Summary Of Resultsmentioning

confidence: 99%

“…Cabergoline is also able to influence a range of serotonergic receptors (196) but again it seemed unlikely that serotonergic mechanisms could underlie our results, particularly when citalopram proved unable to affect SST. Indeed our null result with citalopram is consistent with several studies that were unable to influence action cancellation with serotonergic manipulations (70,75,85,211).…”

Section: Action Cancellationmentioning

confidence: 88%

See 1 more Smart Citation

Neurochemical and neurophysiological bases of executive control

Nandam¹

View full text Add to dashboard Cite

The aim of this work is to further understanding into the biological bases of human executive control through an integration of neuropsychology, psychopharmacology and functional imaging. Executive control includes the prototypical executive functions of response inhibition and error awareness.Response inhibition can be further divided into action cancellation and action restraint, which were assayed with the stop signal (SST) and Error Awareness (EAT) tasks, respectively. The EAT, which is a modified go-no go paradigm, was also used to measure error awareness behaviour. Monoamine neurotransmitters, specifically dopamine, noradrenaline and serotonin, were modulated during task performance with acute doses of methylphenidate (a dopamine and noradrenaline reuptake inhibitor), atomoxetine (a noradrenaline reuptake inhibitor), citalopram (a serotonin reuptake inhibitor) and cabergoline (a D 2 agonist). The pharmacoimaging correlates of task performance were also examined with functional magnetic resonance imaging (fMRI). All experiments adhered to a randomised, double blind, placebo-controlled, crossover design and were limited to 18-35 year old healthy right-handed male participants.In Chapter 1, twenty-four (24) participants received acute doses of methylphenidate (30mg), atomoxetine (60mg), citalopram (30mg) and placebo and performed the SST. Methylphenidate, but not atomoxetine or citalopram, led to a reduction in response time variability and stop-signal reaction time indicating enhanced action cancellation compared with the other drug conditions. This enhancement occurred without change to overall response speed suggesting that methylphenidate was modulating core response inhibition processes rather than simply augmenting overall processing speed.This result argued for the prominence of dopaminergic, rather than adrenergic or serotonergic, mechanisms in action cancellation.In Chapter 2, the pharmacoimaging correlates of action restraint aspect were explored. Twenty-seven (27) males received acute doses of methylphenidate (30mg), atomoxetine (60mg), citalopram (30mg) and placebo whilst undertaking the EAT during fMRI. No-go related BOLD activations were then correlated for each of the drug conditions. Although Inhibitory performance under methylphenidate was numerically superior to the other drug conditions, this difference did not achieve statistical significance. On fMRI, methylphenidate activated, versus placebo, the anterior cingulate cortex, right inferior frontal, left middle frontal, left angular and right superior temporal gyri and right caudate. Atomoxetine activated a broad network of cortical regions.Both methylphenidate and atomoxetine, but not citalopram, activated superior temporal, right inferior frontal and left middle frontal clusters. Citalopram only activated the left inferior occipital lobe. Taking each condition's activations as functionally defined regions of interest, the specificity of no-go related activity was compared across the four conditions. Only methylphenidate demonstrat...

show abstract

Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes

Cited by 39 publications

References 63 publications

Dostinex® and Obsessive Compulsive Disorder

Dostinex® and Obsessive Compulsive Disorder

Preclinical pharmacology, ocular tolerability and ocular hypotensive efficacy of a novel non-peptide bradykinin mimetic small molecule

Neurochemical and neurophysiological bases of executive control

Contact Info

Product

Resources

About